Millennium Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Millennium Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-250,000	Closed	-$2.29M	–	6098
2023 Q1	$2.29M	Buy	250,000 +12,800	+5%	+$105K	﹤0.01%	3307
2022 Q4	$1.7M	Buy	+237,200	New	+$1.66M	﹤0.01%	3703

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Millennium Management's AVDL Position: Q1 2026 in Review

Millennium Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 84,085 shares — an estimated $1.81M sold.

Millennium Management first reported a position in AVDL in Q2 2013 and held it in 43 quarters. The position peaked at $32.9M in Q1 2015. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Millennium Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Millennium Management sold 84,085 Avadel Pharmaceuticals shares in Q1 2026, an estimated $1.81M.
Millennium Management first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 43 quarters.
Millennium Management's Avadel Pharmaceuticals position peaked at $32.9M in Q1 2015.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.